How much did Lipitor’s market share drop after generic competition started?
When generic versions of atorvastatin (Lipitor) began entering the market, Lipitor’s market share fell sharply, reflecting the typical shift from a branded statin to lower-priced generics. Generic uptake accelerated as more competitors received approval and prescriptions moved to the cheapest equivalent option.
What typically happened to Lipitor’s share curve once generics were available?
As generic atorvastatin availability expanded, market share shifted away from the brand in two stages: first, rapid substitution as initial generic supply reached pharmacies and payers; then a further decline as additional generic manufacturers increased availability and drove prices down. During this process, Lipitor’s share generally continued trending downward rather than stabilizing quickly.
Did Lipitor lose share immediately at generic launch?
Usually not evenly. The earliest generic entrants often capture share first, but the total market impact depends on how quickly prescriptions switch, whether insurers place generics on preferred tiers, and how many generic brands are available. Those factors determine how fast Lipitor’s market share erodes right after launch.
Did market share recover after a temporary dip?
Once generic competition becomes established and prescribing patterns normalize, a branded product typically does not regain its prior share because generics remain the primary lower-cost choice. Any rebound would usually require major changes like new product differentiation or coverage/payment shifts that reduce generic advantage.
What data sources are commonly used to measure Lipitor’s market-share change?
Studies and business reporting typically track market share using prescription data from:
- pharmacy claims/retail prescription datasets (often anonymized)
- payer or managed care formularies and utilization reports
- industry analyst estimates that combine multiple data feeds
What I need from you to answer with exact numbers
To quantify “how did Lipitor’s market share change,” I need one missing detail: the time period and geography you mean (for example, US retail prescriptions vs. global, or the specific years around patent expiry). Share can move differently by country and by dataset provider.
If you tell me the region (US or another country) and the years you care about (e.g., around 2011–2012 or another window), I can frame the market-share change in that context.